Karin Rosén moves on from GSK, now play­ing dual roles at Hori­zon; Gilead looks to Jared Baeten to take com­mand of HIV strat­e­gy

GSK and Genen­tech alum Karin Rosén is ex­pand­ing her hori­zons, so to speak, tak­ing on the roles of CSO and EVP, R&D at Hori­zon Ther­a­peu­tics. Rosén de­parts for Hori­zon from her gig at GSK as SVP of US med­ical af­fairs, and she was a med­ical af­fairs ex­ec at Aim­mune be­fore then for a short time. At Genen­tech, where she spent 10 years, she was pro­mot­ed to ther­a­peu­tic area head, im­munol­o­gy and worked on sev­er­al Phase II/III pro­grams in im­munol­o­gy, res­pi­ra­to­ry, al­ler­gy and der­ma­tol­ogy.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.